<DOC>
	<DOCNO>NCT02206568</DOCNO>
	<brief_summary>To compare early pharmacokinetic exposure URAL insulin lispro ( ILisp ) .</brief_summary>
	<brief_title>Pharmacokinetics Ultra-Rapid-Acting Insulin Lispro ( URAL ) Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>To compare total pharmacodynamic response URAL insulin lispro . To compare total pharmacokinetic exposure URAL insulin lispro . To assess safety tolerability URAL insulin lispro .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin , Short-Acting</mesh_term>
	<criteria>1 . Signed informed consent 2 . Male subects age 1865 year inclusive 3 . Type 1 diabetes mellitus diagnose clinically &gt; = 12 month 4 . Treatment multiple daily insulin injection CSII &gt; = 12 month 5 . Current total daily insulin treatment &lt; 1.2 ( I ) U/kg/day 6 . Current total daily bolus insulin treatment &lt; 0.7 ( I ) U/kg/day 7 . Body mass index 18.030.0 kg/m2 inclusive 8 . HbA1c = &lt; 9.0 % local laboratory analysis ( one retest within week permit result last test conclusive ) 9 . Cpeptide = &lt; 0.30 nmol/L 1 . Known suspected hypersensitivity trial product relate product 2 . Previous participation trial . . 3 . Receipt nonmarketed investigational product within 3 month 4 . Clinically significant abnormal haematology , biochemistry , liver enzymes , coagulation screening test 5 . Suffer history life threaten disease clinically significant cardiovascular , respiratory , metabolic , renal , hepatic , gastrointestinal , endocrinological , haematological , dermatological , venereal , neurological , psychiatric disease major disorder 6 . History deep leg vein thrombosis frequent appearance deep leg veinthrombosis 1st degree relative 7 . Cardiac problem define decompensated heart failure ( New York Heart Association class III IV ) time and/or angina pectoris within last 12 month and/or acute myocardial infarction time . 8 . Supine blood pressure screen outside range 90140 mmHg systollic 5090 mmHg diastolic . Pulse outside 50 90 bpm . 9 . Clinically significant abnormal ECG screening . 10 . Proliferative retinopathy maculopathy and/or severe neuropathy , particular autonomic neuropathy . 11 . Any disease condition , inthe opinion Investigator , would represent unacceptable risk subject 's safety . 12 . Subject positive HBsAg , HCVAb 13 . Positive result screen test HIV1 antibody , HIV2 antibody , HIV1 antigen accord locally use diagnostic testing . 14 . History multiple and/or severe allergy drug food history severe anaphylactic reaction . 15 . Subject donate blood plasma past month 500 mL within 3 month . 16 . Surgery trauma significant blood loss ( 500 mL ) within 3 month . 17 . Current treatment systemic ( oral , IV , inhale ) corticosteroid , monoamine oxidase inhibitor , NSAID , prostaglandin blocker , systemic nonselective betablockers , growth hormone ( last 3 month ) , nonroutine vitamin herbal product ( last 2 week ) . Yhyroid hormons allow unless use stable last 3 month . Routine vitamins permit 48 hour prior dose . 18 . Significant history alcoholism and/or drug/chemical abuse per Investigator 's judgement positive result urine drug/alcohol breath test screen screen visit . 19 . Heavy smoker 20 . Not able willing refrain smoking use nicotine . 21 . Recurrent severe hypoglycaemia ( 1 severe hypoglycaemia event last 12 month ) hypoglycaemic unawareness . 22 . Subject mental incapacity language barrier preclude adequate understanding . 23 . Potentially noncompliant uncooperative trial . 24 . Any condition would interfere trial participation evaluation result . 25 . No relevant lipodystrophy within area drug administration Doppler sonography .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>diabetes mellitus</keyword>
	<keyword>phase 1</keyword>
	<keyword>insulin lispro</keyword>
	<keyword>male subject</keyword>
</DOC>